Total amount raised
$37.4 Millions
Latest funding date
05/01/2024
Location
Nabla Bio has successfully raised $26 million in Series A financing, leveraging its proprietary biologically informed machine learning platform to develop antibody drugs. The company has garnered the support of eight investors, including notable names like Fifty Years and Khosla Ventures.
Keep reading to explore the intricacies of Nabla Bio's fundraising journey and the investors backing this innovative platform.
What Is Nabla Bio?
Nabla Bio, founded on May 29, 2020, is a biotechnology company based in Cambridge, Massachusetts. The company was established by Frances Anastassacos and Surge Biswas.
Specializing in biopharma, biotechnology, and machine learning, Nabla Bio employs a team of 11-50 people. The company leverages AI and experimental technologies to design antibodies with atomic precision, aiming to develop new medicines and improve nutrition through novel protein engineering.
How Much Funding Has Nabla Bio Raised?
- Pre-Seed Round
- Amount Raised: $125,000
- Date: August 31, 2021
- Lead Investors: Fifty Years
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To kickstart the company's operations and initial development efforts.
- Grant
- Amount Raised: $256,000
- Date: March 31, 2021
- Lead Investors: National Science Foundation
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support early-stage research and development activities.
- Seed Round
- Amount Raised: $11,000,000
- Date: December 6, 2021
- Lead Investors: Khosla Ventures, Zetta Venture Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To develop AI and wet-lab technologies for precise drug design.
- Series A
- Amount Raised: $26,000,000
- Date: May 14, 2024
- Lead Investors: Radical Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand operations and development efforts, and to support strategic collaborations with major pharmaceutical companies.
Total Amount Raised: $37,381,000. Current Valuation: Not publicly disclosed.
Key Investors
- Radical Ventures
- Details: Radical Ventures is a venture capital firm that focuses on investing in companies leveraging artificial intelligence and other advanced technologies. They led the Series A funding round for Nabla Bio.
- Investment Focus Areas: AI, machine learning, transformative technologies
- Notable Investments: Not publicly disclosed
- Khosla Ventures
- Details: Khosla Ventures is a venture capital firm founded by Vinod Khosla, focusing on impactful technology investments. They participated in Nabla Bio's seed round.
- Investment Focus Areas: Technology, healthcare, sustainability
- Notable Investments: Square, DoorDash, Impossible Foods
- Zetta Venture Partners
- Details: Zetta Venture Partners is a venture capital firm that invests in early-stage companies utilizing artificial intelligence and data analytics. They were key investors in Nabla Bio's seed round.
- Investment Focus Areas: AI, data analytics, enterprise software
- Notable Investments: Not publicly disclosed
- Fifty Years
- Details: Fifty Years is a seed fund that backs entrepreneurs solving the world's biggest problems. They led Nabla Bio's pre-seed round.
- Investment Focus Areas: Biotechnology, sustainability, health
- Notable Investments: Not publicly disclosed
- National Science Foundation
- Details: The National Science Foundation is a government agency that supports fundamental research and education. They provided a grant to Nabla Bio.
- Investment Focus Areas: Science, engineering, education
- Notable Investments: Not publicly disclosed
What's Next for Nabla Bio?
Nabla Bio stands at the cusp of significant growth, driven by its strategic collaborations with pharmaceutical giants like AstraZeneca, Bristol Myers Squibb, and Takeda. These partnerships, valued at over $550 million, offer a substantial opportunity to expand their drug pipeline and refine their AI-driven technologies for precise drug design. The company's focus on multipass membrane proteins, which are notoriously difficult to target, positions it to make groundbreaking advancements in the biopharma industry.
Future fundraising opportunities appear promising as Nabla Bio continues to demonstrate success in its collaborations and technological developments. The recent $26 million Series A funding round, led by Radical Ventures, sets a strong precedent for attracting further investments. However, the company must navigate challenges such as competition from other biotech firms and the technical complexities of scaling their AI and wet-lab technologies.
Use Clay to Get Funding Data
Sales professionals, take your strategy to the next level by leveraging Clay's platform to access comprehensive fundraising data on companies like Nabla Bio and gather other critical business insights.
Sign up for free to start transforming your sales approach today.
